Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
Background The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation befor...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2021-10, Vol.88 (4), p.741-751 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 751 |
|---|---|
| container_issue | 4 |
| container_start_page | 741 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 88 |
| creator | Bellesoeur, Audrey Gataa, Ithar Jouinot, Anne Mershati, Sarah El Piketty, Anne-Catherine Tlemsani, Camille Balakirouchenane, David Monribot, Anthia Vidal, Michel Batista, Rui de Percin, Sixtine Villeminey, Clémentine Alexandre, Jérôme Goldwasser, François Blanchet, Benoit Boudou-Rouquette, Pascaline Thomas-Schoemann, Audrey |
| description | Background
The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.
Patients and methods
We performed a retrospective review of consecutive sarcoma patients starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A pharmacist performed medication reconciliation and established an early toxicity risk assessment. Potential DDI with antitumor drugs were identified using Micromedex electronic software.
Results
One hundred and twenty-two soft-tissue and 80 bone sarcoma patients (103 males, median age 50 years,) were included before CT (86%) or TKI (14%). The median number of medications was 3; 34 patients (22% of patients with medication reconciliation) reported complementary medicine use. 37 potential DDI classified as major, were identified (12% of the 243 pre-therapeutic assessments). In multivariate analysis, TKI (
p
|
| doi_str_mv | 10.1007/s00280-021-04311-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2561653019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2561653019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-1043c208763d5a577b2c61082dae7c1a7cc0463ccb27b613c2b6b906691ebae73</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EEqXwA6wssTaMH3ESdgjxkirBAtaW4zpp2iYutovoCv6BP-RLcBskdqxGI51zR3MROqVwTgHyiwDACiDAKAHBKSViD42o4IxAIfg-GgEXgmQ5iEN0FMIcAATlfIQ-nrx900vbG4tdjad-3Xx_fm0HbvtovTaxdX1ICw7aG9dpvNKxtX0Ml3hhN9i75c6MM4tXM-07bdoQd3Lj9VbGtfM4uvfWtDHxbVjgTve6sV1KOUYHtV4Ge_I7x-jl9ub5-p5MHu8erq8mxPBSRkLTV4ZBkUs-zXSW5xUzkkLBptrmhurcGBCSG1OxvJI0sZWsSpCypLZKCB-jsyF35d3r2oao5m7t-3RSsUxSmXGgZaLYQBnvQvC2VivfdtpvFAW1LVoNRatUtNoVrUSS-CCFBPeN9X_R_1g_SqyDpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561653019</pqid></control><display><type>article</type><title>Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management</title><source>Springer Nature - Complete Springer Journals</source><creator>Bellesoeur, Audrey ; Gataa, Ithar ; Jouinot, Anne ; Mershati, Sarah El ; Piketty, Anne-Catherine ; Tlemsani, Camille ; Balakirouchenane, David ; Monribot, Anthia ; Vidal, Michel ; Batista, Rui ; de Percin, Sixtine ; Villeminey, Clémentine ; Alexandre, Jérôme ; Goldwasser, François ; Blanchet, Benoit ; Boudou-Rouquette, Pascaline ; Thomas-Schoemann, Audrey</creator><creatorcontrib>Bellesoeur, Audrey ; Gataa, Ithar ; Jouinot, Anne ; Mershati, Sarah El ; Piketty, Anne-Catherine ; Tlemsani, Camille ; Balakirouchenane, David ; Monribot, Anthia ; Vidal, Michel ; Batista, Rui ; de Percin, Sixtine ; Villeminey, Clémentine ; Alexandre, Jérôme ; Goldwasser, François ; Blanchet, Benoit ; Boudou-Rouquette, Pascaline ; Thomas-Schoemann, Audrey</creatorcontrib><description>Background
The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.
Patients and methods
We performed a retrospective review of consecutive sarcoma patients starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A pharmacist performed medication reconciliation and established an early toxicity risk assessment. Potential DDI with antitumor drugs were identified using Micromedex electronic software.
Results
One hundred and twenty-two soft-tissue and 80 bone sarcoma patients (103 males, median age 50 years,) were included before CT (86%) or TKI (14%). The median number of medications was 3; 34 patients (22% of patients with medication reconciliation) reported complementary medicine use. 37 potential DDI classified as major, were identified (12% of the 243 pre-therapeutic assessments). In multivariate analysis, TKI (
p
< 0.0001), proton pump inhibitor (
p
= 0.026) and antidepressant (
p
< 0.001) were identified as risk factors of DDI (
p
< 0.02). Only marital status (
p
= 0.003) was associated with complementary medicine use. A pharmacist performed 157 medication reconciliations and made 71 interventions among 59 patients (37%). In multivariate analysis, factors associated with pharmacist intervention were: complementary medicines (
p
= 0.004), drugs number (
p
= 0.005) and treatment with TKI (
p
= 0.0002)
Conclusions
Clinical interventions on DDI are more frequently required among sarcoma patients treated with TKI than CT. Multidisciplinary risk assessment including a medication reconciliation by a pharmacist could be crucial to prevent DDI with TKI.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-021-04311-4</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Alternative medicine ; Antidepressants ; Bone tumors ; Cancer Research ; Chemotherapy ; Drug interactions ; Drugs ; Enzyme inhibitors ; Evaluation ; Kinases ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Oncology ; Original Article ; Patients ; Pharmacology/Toxicology ; Protein-tyrosine kinase ; Proton pump inhibitors ; Reconciliation ; Risk analysis ; Risk assessment ; Risk factors ; Risk management ; Sarcoma ; Toxicity ; Tyrosine</subject><ispartof>Cancer chemotherapy and pharmacology, 2021-10, Vol.88 (4), p.741-751</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-1043c208763d5a577b2c61082dae7c1a7cc0463ccb27b613c2b6b906691ebae73</citedby><cites>FETCH-LOGICAL-c396t-1043c208763d5a577b2c61082dae7c1a7cc0463ccb27b613c2b6b906691ebae73</cites><orcidid>0000-0002-8240-1478</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-021-04311-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-021-04311-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,41475,42544,51306</link.rule.ids></links><search><creatorcontrib>Bellesoeur, Audrey</creatorcontrib><creatorcontrib>Gataa, Ithar</creatorcontrib><creatorcontrib>Jouinot, Anne</creatorcontrib><creatorcontrib>Mershati, Sarah El</creatorcontrib><creatorcontrib>Piketty, Anne-Catherine</creatorcontrib><creatorcontrib>Tlemsani, Camille</creatorcontrib><creatorcontrib>Balakirouchenane, David</creatorcontrib><creatorcontrib>Monribot, Anthia</creatorcontrib><creatorcontrib>Vidal, Michel</creatorcontrib><creatorcontrib>Batista, Rui</creatorcontrib><creatorcontrib>de Percin, Sixtine</creatorcontrib><creatorcontrib>Villeminey, Clémentine</creatorcontrib><creatorcontrib>Alexandre, Jérôme</creatorcontrib><creatorcontrib>Goldwasser, François</creatorcontrib><creatorcontrib>Blanchet, Benoit</creatorcontrib><creatorcontrib>Boudou-Rouquette, Pascaline</creatorcontrib><creatorcontrib>Thomas-Schoemann, Audrey</creatorcontrib><title>Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Background
The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.
Patients and methods
We performed a retrospective review of consecutive sarcoma patients starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A pharmacist performed medication reconciliation and established an early toxicity risk assessment. Potential DDI with antitumor drugs were identified using Micromedex electronic software.
Results
One hundred and twenty-two soft-tissue and 80 bone sarcoma patients (103 males, median age 50 years,) were included before CT (86%) or TKI (14%). The median number of medications was 3; 34 patients (22% of patients with medication reconciliation) reported complementary medicine use. 37 potential DDI classified as major, were identified (12% of the 243 pre-therapeutic assessments). In multivariate analysis, TKI (
p
< 0.0001), proton pump inhibitor (
p
= 0.026) and antidepressant (
p
< 0.001) were identified as risk factors of DDI (
p
< 0.02). Only marital status (
p
= 0.003) was associated with complementary medicine use. A pharmacist performed 157 medication reconciliations and made 71 interventions among 59 patients (37%). In multivariate analysis, factors associated with pharmacist intervention were: complementary medicines (
p
= 0.004), drugs number (
p
= 0.005) and treatment with TKI (
p
= 0.0002)
Conclusions
Clinical interventions on DDI are more frequently required among sarcoma patients treated with TKI than CT. Multidisciplinary risk assessment including a medication reconciliation by a pharmacist could be crucial to prevent DDI with TKI.</description><subject>Alternative medicine</subject><subject>Antidepressants</subject><subject>Bone tumors</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Drug interactions</subject><subject>Drugs</subject><subject>Enzyme inhibitors</subject><subject>Evaluation</subject><subject>Kinases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Protein-tyrosine kinase</subject><subject>Proton pump inhibitors</subject><subject>Reconciliation</subject><subject>Risk analysis</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>Risk management</subject><subject>Sarcoma</subject><subject>Toxicity</subject><subject>Tyrosine</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtOwzAQRS0EEqXwA6wssTaMH3ESdgjxkirBAtaW4zpp2iYutovoCv6BP-RLcBskdqxGI51zR3MROqVwTgHyiwDACiDAKAHBKSViD42o4IxAIfg-GgEXgmQ5iEN0FMIcAATlfIQ-nrx900vbG4tdjad-3Xx_fm0HbvtovTaxdX1ICw7aG9dpvNKxtX0Ml3hhN9i75c6MM4tXM-07bdoQd3Lj9VbGtfM4uvfWtDHxbVjgTve6sV1KOUYHtV4Ge_I7x-jl9ub5-p5MHu8erq8mxPBSRkLTV4ZBkUs-zXSW5xUzkkLBptrmhurcGBCSG1OxvJI0sZWsSpCypLZKCB-jsyF35d3r2oao5m7t-3RSsUxSmXGgZaLYQBnvQvC2VivfdtpvFAW1LVoNRatUtNoVrUSS-CCFBPeN9X_R_1g_SqyDpw</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Bellesoeur, Audrey</creator><creator>Gataa, Ithar</creator><creator>Jouinot, Anne</creator><creator>Mershati, Sarah El</creator><creator>Piketty, Anne-Catherine</creator><creator>Tlemsani, Camille</creator><creator>Balakirouchenane, David</creator><creator>Monribot, Anthia</creator><creator>Vidal, Michel</creator><creator>Batista, Rui</creator><creator>de Percin, Sixtine</creator><creator>Villeminey, Clémentine</creator><creator>Alexandre, Jérôme</creator><creator>Goldwasser, François</creator><creator>Blanchet, Benoit</creator><creator>Boudou-Rouquette, Pascaline</creator><creator>Thomas-Schoemann, Audrey</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-8240-1478</orcidid></search><sort><creationdate>20211001</creationdate><title>Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management</title><author>Bellesoeur, Audrey ; Gataa, Ithar ; Jouinot, Anne ; Mershati, Sarah El ; Piketty, Anne-Catherine ; Tlemsani, Camille ; Balakirouchenane, David ; Monribot, Anthia ; Vidal, Michel ; Batista, Rui ; de Percin, Sixtine ; Villeminey, Clémentine ; Alexandre, Jérôme ; Goldwasser, François ; Blanchet, Benoit ; Boudou-Rouquette, Pascaline ; Thomas-Schoemann, Audrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-1043c208763d5a577b2c61082dae7c1a7cc0463ccb27b613c2b6b906691ebae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alternative medicine</topic><topic>Antidepressants</topic><topic>Bone tumors</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Drug interactions</topic><topic>Drugs</topic><topic>Enzyme inhibitors</topic><topic>Evaluation</topic><topic>Kinases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Protein-tyrosine kinase</topic><topic>Proton pump inhibitors</topic><topic>Reconciliation</topic><topic>Risk analysis</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>Risk management</topic><topic>Sarcoma</topic><topic>Toxicity</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bellesoeur, Audrey</creatorcontrib><creatorcontrib>Gataa, Ithar</creatorcontrib><creatorcontrib>Jouinot, Anne</creatorcontrib><creatorcontrib>Mershati, Sarah El</creatorcontrib><creatorcontrib>Piketty, Anne-Catherine</creatorcontrib><creatorcontrib>Tlemsani, Camille</creatorcontrib><creatorcontrib>Balakirouchenane, David</creatorcontrib><creatorcontrib>Monribot, Anthia</creatorcontrib><creatorcontrib>Vidal, Michel</creatorcontrib><creatorcontrib>Batista, Rui</creatorcontrib><creatorcontrib>de Percin, Sixtine</creatorcontrib><creatorcontrib>Villeminey, Clémentine</creatorcontrib><creatorcontrib>Alexandre, Jérôme</creatorcontrib><creatorcontrib>Goldwasser, François</creatorcontrib><creatorcontrib>Blanchet, Benoit</creatorcontrib><creatorcontrib>Boudou-Rouquette, Pascaline</creatorcontrib><creatorcontrib>Thomas-Schoemann, Audrey</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bellesoeur, Audrey</au><au>Gataa, Ithar</au><au>Jouinot, Anne</au><au>Mershati, Sarah El</au><au>Piketty, Anne-Catherine</au><au>Tlemsani, Camille</au><au>Balakirouchenane, David</au><au>Monribot, Anthia</au><au>Vidal, Michel</au><au>Batista, Rui</au><au>de Percin, Sixtine</au><au>Villeminey, Clémentine</au><au>Alexandre, Jérôme</au><au>Goldwasser, François</au><au>Blanchet, Benoit</au><au>Boudou-Rouquette, Pascaline</au><au>Thomas-Schoemann, Audrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><date>2021-10-01</date><risdate>2021</risdate><volume>88</volume><issue>4</issue><spage>741</spage><epage>751</epage><pages>741-751</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Background
The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.
Patients and methods
We performed a retrospective review of consecutive sarcoma patients starting chemotherapy (CT) or Tyrosine kinase inhibitor (TKI). A pharmacist performed medication reconciliation and established an early toxicity risk assessment. Potential DDI with antitumor drugs were identified using Micromedex electronic software.
Results
One hundred and twenty-two soft-tissue and 80 bone sarcoma patients (103 males, median age 50 years,) were included before CT (86%) or TKI (14%). The median number of medications was 3; 34 patients (22% of patients with medication reconciliation) reported complementary medicine use. 37 potential DDI classified as major, were identified (12% of the 243 pre-therapeutic assessments). In multivariate analysis, TKI (
p
< 0.0001), proton pump inhibitor (
p
= 0.026) and antidepressant (
p
< 0.001) were identified as risk factors of DDI (
p
< 0.02). Only marital status (
p
= 0.003) was associated with complementary medicine use. A pharmacist performed 157 medication reconciliations and made 71 interventions among 59 patients (37%). In multivariate analysis, factors associated with pharmacist intervention were: complementary medicines (
p
= 0.004), drugs number (
p
= 0.005) and treatment with TKI (
p
= 0.0002)
Conclusions
Clinical interventions on DDI are more frequently required among sarcoma patients treated with TKI than CT. Multidisciplinary risk assessment including a medication reconciliation by a pharmacist could be crucial to prevent DDI with TKI.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00280-021-04311-4</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8240-1478</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2021-10, Vol.88 (4), p.741-751 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_2561653019 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Alternative medicine Antidepressants Bone tumors Cancer Research Chemotherapy Drug interactions Drugs Enzyme inhibitors Evaluation Kinases Medicine Medicine & Public Health Multivariate analysis Oncology Original Article Patients Pharmacology/Toxicology Protein-tyrosine kinase Proton pump inhibitors Reconciliation Risk analysis Risk assessment Risk factors Risk management Sarcoma Toxicity Tyrosine |
| title | Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A22%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20drug%E2%80%93drug%20interactions%20in%20sarcoma%20patients:%20key%20role%20of%20the%20pharmacist%20integration%20for%20toxicity%20risk%20management&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Bellesoeur,%20Audrey&rft.date=2021-10-01&rft.volume=88&rft.issue=4&rft.spage=741&rft.epage=751&rft.pages=741-751&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-021-04311-4&rft_dat=%3Cproquest_cross%3E2561653019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561653019&rft_id=info:pmid/&rfr_iscdi=true |